The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma

Respiratory Research

Volumn 11, Issue , 2010, Pages

  Singh, Dave ^a,b   Petavy, Frank ^c   Macdonald, Alex J ^c   Lazaar, Aili L ^d   O'Connor, Brian J ^e  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b Medicines Evaluation Unit   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; GSK 256066; METHACHOLINE; NITRIC OXIDE; PLACEBO; 6 ((3 ((DIMETHYLAMINO)CARBONYL)PHENYL)SULFONYL) 8 METHYL 4 ((3 METHYLOXYPHENYL)AMINO) 3 QUINOLINECARBOXAMIDE; 6-((3-((DIMETHYLAMINO)CARBONYL)PHENYL)SULFONYL)-8-METHYL-4-((3-METHYLOXYPHENYL)AMINO)-3-QUINOLINECARBOXAMIDE; AMINOQUINOLINE DERIVATIVE; PHOSPHODIESTERASE IV; SULFONE;

ADULT; AGED; ALLERGIC ASTHMA; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CLINICAL ARTICLE; COUGHING; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG TOLERABILITY; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNOREACTIVITY; LUNG FUNCTION; MAXIMUM PLASMA CONCENTRATION; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; WHEEZING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; FEMALE; INHALATION TEST; INHALATIONAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; AMINOQUINOLINES; ASTHMA; BRONCHIAL PROVOCATION TESTS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; FEMALE; HUMANS; MALE; MIDDLE AGED; SULFONES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77952491177     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-11-26     Document Type: Article

References (31)

1. Global strategy for asthma management and prevention. Last updated 2007., http://www.ginasthma.com
2. Partridge MR, Molen T, Myrseth SE, Busse WW. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med 2006, 6:13. 10.1186/1471-2466-6-13, 1483837, 16772035.
3. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, Pedersen SE. Can guideline defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004, 170:836-844. 10.1164/rccm.200401-033OC, 15256389.
4. Schudt C, Gantner F, Tenors H, Hatzelmann A. Therapeutic potential of selective PDE inhibitors in asthma. Pulm Pharmacol Ther 1999, 12:123-9. 10.1006/pupt.1999.0182, 10373395.
5. Spina D. PDE4 inhibitors: current status. Br J Pharmacol 2008, 155:308-15. 10.1038/bjp.2008.307, 2567892, 18660825.
6. Boswell-Smith V, Cazzola M, Page CP. Are phosphodiesterase 4 inhibitors just more theophylline?. J Allergy Clin Immunol 2006, 117:1237-43. 10.1016/j.jaci.2006.02.045, 16750981.
7. Sessler CN. Theophylline toxicity: clinical features of 116 consecutive cases. Am J Med 1990, 88(6):567-76. 10.1016/0002-9343(90)90519-J, 2189301.
8. Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998, 157:351-70.
9. Underwood DC, Osborn RT, Novak LB, Matthews JK, Newsholme SJ, Undem BJ, Hand JM, Torphy TJ. Inhibition of antigen induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP specific phosphodiesterase inhibtor, rolipram. J Pharmacol Exp Ther 1993, 266:306-313.
10. Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 2001, 297:280-90.
11. Harbinson PL, MacLeod D, Hawksworth R, O'Toole S, Sullivan PJ, Heath P, Kilfeather S, Page CP, Costello J, Holgate ST, Lee TH. The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects. Eur Respir J 1997, 10:1008-14. 10.1183/09031936.97.10051008, 9163639.
12. van Schalkwyk E, Strydom K, Williams Z, Venter L, Leichtl S, Schmid-Wirlitsch C, Bredenbröker D, Bardin PG. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J Allergy Clin Immunol 2005, 116:292-8. 10.1016/j.jaci.2005.04.023, 16083782.
13. Timmer W, Leclerc V, Birraux G, Neuhäuser M, Hatzelmann A, Bethke T, Wurst W. The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo. J Clin Pharmacol 2002, 42:297-303. 10.1177/00912700222011328, 11865966.
14. Bousquet J, Aubier M, Sastre J, Izquierdo JL, Adler LM, Hofbauer P, Rost KD, Harnest U, Kroemer B, Albrecht A, Bredenbröker D. Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma. Allergy 2006, 61:72-8.
15. Calverley PM, Sanchez-Toril F, McIvor A, Teichmann P, Bredenbroeker D, Fabbri LM. Effect of 1-Year Treatment with Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2007, 176:154-61. 10.1164/rccm.200610-1563OC, 17463412.
16. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF, . M2-127 and M2-128 study groups Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009, 374:695-703. 10.1016/S0140-6736(09)61252-6, 19716961, M2-127 and M2-128 study groups.
17. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ, . M2-124 and M2-125 study groups Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009, 374:685-94. 10.1016/S0140-6736(09)61255-1, 19716960, M2-124 and M2-125 study groups.
18. Knowles RG, Ball DI, Gascoigne MH, Tralau-Stewart C, Nials AT. In-vivo characterisation of GSK25 an exceptionally high affinity and selective PDE4 inhibitor suitable for topical administration. Am J Respir Crit Care Med 2009, 179:A4582.
19. Singh SD, Richards D, Knowles RG, Schwartz S, Woodcock AA, Langley SJ, O'Connor BJ. Selective inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma. Am J Respir Crit Care Med 2007, 176:988-93. 10.1164/rccm.200704-588OC, 17717202.
20. Palmqvist M, Bruce C, Sjöstrand M, Arvidsson P, Lötvall J. Differential effects of fluticasone and. Allergy 2005, 60:65-70. 10.1111/j.1398-9995.2005.00633.x, 15575933.
21. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007, 370:1422-31. 10.1016/S0140-6736(07)61600-6, 17950857.
22. Duong M, Gauvreau G, Watson R, Obminski G, Strinich T, Evans M, Howie K, Killian K, O'Byrne PM. The effects of inhaled budesonide and formoterol in combination and alone when given directly after allergen challenge. J Allergy Clin Immunol 2007, 119:322-7. 10.1016/j.jaci.2006.10.018, 17141859.
23. Gauvreau GM, Boulet LP, Postma DS, Kawayama T, Watson RM, Duong M, Deschesnes F, De Monchy JG, O'Byrne PM. Effect of low-dose ciclesonide on allergen-induced responses in subjects with mild allergic asthma. J Allergy Clin Immunol 2005, 116:285-91. 10.1016/j.jaci.2005.05.021, 16083781.
24. Inman MD, Watson RM, Rerecich T, Gauvreau GM, Lutsky BN, Stryszak P, O'Byrne PM. Dose-dependent effects of inhaled mometasone furoate on airway function and inflammation after allergen inhalation challenge. Am J Respir Crit Care Med 2001, 164:569-74.
25. Virchow JC, Walker C, Hafner D, Kortsik C, Werner P, Matthys H, Kroegel C. T cells and cytokines in bronchoalveolar lavage fluid after segmental allergen provocation in atopic asthma. Am J Respir Crit Care Med 1995, 151:960-8.
26. Adcock IM, Ito K, Barnes PJ. Glucocorticoids. Effects on gene transcription. Proc Am Thorac Soc 2004, 1:247-254. 10.1513/pats.200402-001MS, 16113442.
27. Peter D, Jin SL, Conti M, Hatzelmann A, Zitt C. Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: predominant role of PDE4D. J Immunol 2007, 178:4820-31.
28. Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005, 352:2163-73. 10.1056/NEJMoa043596, 15914548.
29. Kanniess F, Richter K, Böhme S, Jörres RA, Magnussen H. Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma. Eur Respir J 2002, 20:853-8. 10.1183/09031936.02.00244602, 12412675.
30. Bethke TD, Böhmer GM, Hermann R, Hauns B, Fux R, Mörike K, David M, Knoerzer D, Wurst W, Gleiter CH. Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor. J Clin Pharmacol 2007, 47:26-36. 10.1177/0091270006294529, 17192499.
31. Vestbo J, Tan L, Atkinson G, Ward J, . UK-500, 001 Global Study Team A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD. Eur Respir J 2009, 33:1039-44. 10.1183/09031936.00068908, 19213793, UK-500, 001 Global Study Team.